The antibody-mediated blockade of PD-L1 can result in durable tumor regression and can prolong stabilization of disease in patients with advanced cancers, including non–small-cell lung cancer (NSCLC), melanoma, and renal-cell cancer12,14. The gene discussed is CD274; the disease is neoplasm.